Serious adverse events
|
Rivaroxaban 2.5mg + Aspirin 100mg |
Rivaroxaban Placebo + Aspirin 100mg |
Rivaroxaban 5mg + Aspirin Placebo |
Total subjects affected by serious adverse events
|
|
|
|
subjects affected / exposed
|
781 / 9135 (8.55%) |
715 / 9108 (7.85%) |
755 / 9109 (8.29%) |
number of deaths (all causes)
|
631 |
657 |
653 |
number of deaths resulting from adverse events
|
185 |
181 |
166 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
Acute leukaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Acute myeloid leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Adenocarcinoma gastric
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Adenocarcinoma of colon
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Adenoma benign
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
B-cell lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Basal cell carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bile duct cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Biliary neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Bladder cancer
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
8 / 9108 (0.09%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 8 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 6 |
0 / 0 |
Bladder cancer recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bone cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bowen's disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain neoplasm malignant
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Breast cancer
|
|
|
|
subjects affected / exposed
|
7 / 9135 (0.08%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
Bronchial carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
Cervix carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Cholangiocarcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
Colon cancer
|
|
|
|
subjects affected / exposed
|
10 / 9135 (0.11%) |
6 / 9108 (0.07%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 6 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 1 |
Cholesteatoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diffuse large B-cell lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fibroma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colon cancer stage IV
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Gallbladder cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Gastric cancer
|
|
|
|
subjects affected / exposed
|
8 / 9135 (0.09%) |
6 / 9108 (0.07%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 6 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 4 |
0 / 1 |
Gastrointestinal carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Hodgkin's disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Haemangioma of skin
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Laryngeal cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intracranial tumour haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypopharyngeal cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Laryngeal neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Leukaemia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Lipoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung adenocarcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 3 |
0 / 1 |
Lung carcinoma cell type unspecified stage IV
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Malignant neoplasm of renal pelvis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Malignant melanoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Malignant neoplasm of spermatic cord
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Meningioma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Meningioma benign
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mesothelioma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Mesothelioma malignant
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Metastases to bone
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Metastases to liver
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
Metastases to lung
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myelodysplastic syndrome
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Metastatic malignant melanoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Metastases to neck
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Neoplasm malignant
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
7 / 9108 (0.08%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 7 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 7 |
0 / 5 |
Oesophageal carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
Pancreatic carcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
2 / 9108 (0.02%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 5 |
Pancreatic carcinoma metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
Papillary thyroid cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Penile cancer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostate cancer metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Plasma cell myeloma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Polycythaemia vera
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostate cancer recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rectal cancer
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Rectal adenocarcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Renal cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retroperitoneal cancer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Skin cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Small cell lung cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma of lung
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Small intestine carcinoma metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Tongue neoplasm malignant stage unspecified
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma of the cervix
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tonsil cancer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transitional cell carcinoma
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Uterine leiomyoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tracheal cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Lung cancer metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
5 / 9108 (0.05%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 5 |
0 / 1 |
Colon adenoma
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metastatic renal cell carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Metastases to peritoneum
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Renal cancer metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Small intestine carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Brain cancer metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Hepatic cancer metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Rectal cancer metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metastatic carcinoma of the bladder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Colon cancer metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Prostate cancer
|
|
|
|
subjects affected / exposed
|
15 / 9135 (0.16%) |
6 / 9108 (0.07%) |
10 / 9109 (0.11%) |
occurrences causally related to treatment / all
|
0 / 15 |
1 / 6 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 5 |
0 / 1 |
0 / 1 |
Metastases to central nervous system
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Extradural neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung neoplasm malignant
|
|
|
|
subjects affected / exposed
|
20 / 9135 (0.22%) |
15 / 9108 (0.16%) |
15 / 9109 (0.16%) |
occurrences causally related to treatment / all
|
0 / 21 |
0 / 16 |
1 / 15 |
deaths causally related to treatment / all
|
0 / 19 |
0 / 15 |
0 / 12 |
Cancer pain
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Brain neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Benign renal neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Metastatic neoplasm
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
Colorectal cancer
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
Adrenal neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Malignant mesenchymoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pituitary tumour benign
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral nervous system neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Splenic marginal zone lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tonsillar neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrooesophageal cancer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Colon cancer stage 0
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ameloblastoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gallbladder cancer metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Intraductal papillary mucinous neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Malignant neoplasm of unknown primary site
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Hepatic cancer
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
5 / 9108 (0.05%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 5 |
0 / 2 |
Hepatocellular carcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
Central nervous system neuroblastoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Papillary cystadenoma lymphomatosum
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine benign neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Adrenal gland cancer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Neuroendocrine tumour of the lung
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Adenocarcinoma metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
Follicular lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
Aortic aneurysm
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aortic stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aortic thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Circulatory collapse
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arteriosclerosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Orthostatic hypotension
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral ischaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypotension
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive crisis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renovascular hypertension
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Embolism arterial
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertension
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Varicose ulceration
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thrombophlebitis superficial
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Varicose vein
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Iliac artery stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemodynamic instability
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Dry gangrene
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Shock haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral artery occlusion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral artery aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive emergency
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive urgency
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aortic rupture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Peripheral venous disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
Peripheral artery aneurysm rupture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atheroembolism
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Surgical and medical procedures
|
|
|
|
Carotid endarterectomy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous fistula operation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystectomy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery surgery
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Foot amputation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric polypectomy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hernia hiatus repair
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia repair
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Knee arthroplasty
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mole excision
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ptosis repair
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nasal polypectomy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Umbilical hernia repair
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transurethral prostatectomy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Glaucoma surgery
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac pacemaker replacement
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronary angioplasty
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes mellitus management
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transurethral bladder resection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sigmoidectomy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hospitalisation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral artery angioplasty
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Joint arthroplasty
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hernia repair
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin neoplasm excision
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Shoulder operation
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tooth extraction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cataract operation
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
6 / 9108 (0.07%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 8 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder neoplasm surgery
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal endoscopic therapy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular graft
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Stoma closure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Catheter management
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Large intestinal polypectomy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
|
Asthenia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chest pain
|
|
|
|
subjects affected / exposed
|
10 / 9135 (0.11%) |
6 / 9108 (0.07%) |
14 / 9109 (0.15%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 6 |
0 / 14 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chest discomfort
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Death
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
7 / 9108 (0.08%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 5 |
0 / 7 |
0 / 6 |
Generalised oedema
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Euthanasia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Face oedema
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gait disturbance
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Malaise
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Impaired healing
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hernia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oedema peripheral
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mucosal inflammation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sudden death
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Pyrexia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pain
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral swelling
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
General physical health deterioration
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Nodule
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Unevaluable event
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Accidental death
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
Non-cardiac chest pain
|
|
|
|
subjects affected / exposed
|
10 / 9135 (0.11%) |
8 / 9108 (0.09%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 8 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Stent-graft endoleak
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular stent stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Medical device site erosion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Multiple organ dysfunction syndrome
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 1 |
Lithiasis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
|
Contrast media reaction
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anaphylactic reaction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypersensitivity
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Food allergy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anti-neutrophil cytoplasmic antibody positive vasculitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Social circumstances
|
|
|
|
Pregnancy of partner
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
Prostatic haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostatitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Uterine polyp
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pelvic prolapse
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gynaecomastia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Benign prostatic hyperplasia
|
|
|
|
subjects affected / exposed
|
7 / 9135 (0.08%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Uterine prolapse
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Asthma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Asphyxia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
Acute respiratory failure
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
8 / 9108 (0.09%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 9 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 4 |
0 / 2 |
Acute respiratory distress syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Acute pulmonary oedema
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epistaxis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea exertional
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Emphysema
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Dyspnoea
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
4 / 9108 (0.04%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
Cough
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic obstructive pulmonary disease
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
7 / 9108 (0.08%) |
13 / 9109 (0.14%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 3 |
Choking
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Interstitial lung disease
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Laryngeal oedema
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Nasal polyps
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pleural effusion
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
5 / 9108 (0.05%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
1 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Pleurisy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pleuritic pain
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary embolism
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary fibrosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Pulmonary hypertension
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumothorax
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia aspiration
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Pulmonary vasculitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Respiratory disorder
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Respiratory distress
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Respiratory failure
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
9 / 9108 (0.10%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 9 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 5 |
0 / 8 |
0 / 7 |
Sleep apnoea syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Throat irritation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory acidosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vocal cord polyp
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary mass
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchial polyp
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Laryngeal mass
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Acquired diaphragmatic eventration
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Obstructive airways disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cough variant asthma
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Acute interstitial pneumonitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Organising pneumonia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Upper airway obstruction
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Negative pressure pulmonary oedema
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
Alcohol abuse
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anxiety
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Completed suicide
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 3 |
Delirium
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Confusional state
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Depression
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mania
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Insomnia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Panic attack
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Stereotypy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mental status changes
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Suicide attempt
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
Acute hepatic failure
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bile duct stone
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
3 / 9108 (0.03%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Biliary colic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis acute
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
|
subjects affected / exposed
|
10 / 9135 (0.11%) |
12 / 9108 (0.13%) |
9 / 9109 (0.10%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 12 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Cholecystitis chronic
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis acute
|
|
|
|
subjects affected / exposed
|
7 / 9135 (0.08%) |
10 / 9108 (0.11%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 10 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholelithiasis
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
6 / 9108 (0.07%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholestasis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic failure
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
Cirrhosis alcoholic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Jaundice
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis toxic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Jaundice cholestatic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Bile duct stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Liver disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic mass
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Drug-induced liver injury
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Biliary obstruction
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
Amylase increased
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
2 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aspartate aminotransferase increased
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood pressure increased
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood glucose abnormal
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Biopsy prostate
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchoscopy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Catheterisation cardiac
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemoglobin decreased
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colonoscopy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
HIV test positive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lipase increased
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Liver function test abnormal
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostatic specific antigen increased
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Weight decreased
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urological examination
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Angiogram peripheral
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Computerised tomogram thorax
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anticoagulation drug level above therapeutic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood electrolytes abnormal
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic enzyme increased
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Angiocardiogram
|
|
|
|
subjects affected / exposed
|
10 / 9135 (0.11%) |
12 / 9108 (0.13%) |
9 / 9109 (0.10%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 14 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis B core antibody positive
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Influenza A virus test positive
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Stenotrophomonas test positive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
Alcohol poisoning
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blindness traumatic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Burns second degree
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Carbon monoxide poisoning
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Chemical poisoning
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Fall
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Extradural haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Concussion
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Clavicle fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Femoral neck fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Foreign body in eye
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Femur fracture
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Gun shot wound
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hand fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hip fracture
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Head injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Incisional hernia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Incisional hernia, obstructive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ligament sprain
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Multiple injuries
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Poisoning deliberate
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Overdose
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Radius fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal cord injury cervical
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rib fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Road traffic accident
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
3 / 9108 (0.03%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 3 |
0 / 3 |
Spinal compression fracture
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Subdural haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ulna fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tibia fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tendon rupture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Wound secretion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cervical vertebral fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Muscle strain
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Contusion
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thermal burn
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Brain contusion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infusion related reaction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative renal failure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Wound necrosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative ileus
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Wound evisceration
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Pelvic fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder injury
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chest injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Skull fracture
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Limb injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular bypass dysfunction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular anastomosis aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Limb crushing injury
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural swelling
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Airway burns
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Toxicity to various agents
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Craniocerebral injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Procedural intestinal perforation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Traumatic haemothorax
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Congenital, familial and genetic disorders
|
|
|
|
Hydrocele
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fabry's disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
Acute myocardial infarction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Angina pectoris
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arrhythmia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrial fibrillation
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
11 / 9108 (0.12%) |
7 / 9109 (0.08%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 11 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrial flutter
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block complete
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac arrest
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Bradycardia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery disease
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure congestive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardio-respiratory arrest
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
Cor pulmonale
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Cardiac failure chronic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Supraventricular tachycardia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial ischaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular extrasystoles
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dressler's syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sinus node dysfunction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac ventricular thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery perforation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular tachycardia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
|
Amyotrophic lateral sclerosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Amnesia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Altered state of consciousness
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bell's palsy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
Carpal tunnel syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Carotid artery stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral infarction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral venous thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrospinal fluid leakage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dementia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cervicobrachial syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrovascular accident
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dementia Alzheimer's type
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Demyelination
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Depressed level of consciousness
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dizziness
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Encephalopathy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epilepsy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Facial paralysis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoglycaemic coma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Loss of consciousness
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Headache
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Generalised tonic-clonic seizure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hemianopia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Migraine
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Monoplegia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myasthenia gravis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nerve compression
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Neuropathy peripheral
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Motor neurone disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post herpetic neuralgia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Presyncope
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sciatica
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Polyneuropathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peroneal nerve palsy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Paraesthesia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Subarachnoid haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transient global amnesia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Temporal lobe epilepsy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Syncope
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
7 / 9108 (0.08%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 6 |
1 / 7 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Status epilepticus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal cord compression
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Seizure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
3 / 9108 (0.03%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Transient ischaemic attack
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Uraemic encephalopathy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Vertebrobasilar insufficiency
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vertigo CNS origin
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
VIth nerve paralysis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain oedema
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thalamus haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cervical radiculopathy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cognitive disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular dementia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cubital tunnel syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic inflammatory demyelinating polyradiculoneuropathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Putamen haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain injury
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Neuromuscular pain
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
Haemolytic anaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypochromic anaemia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Febrile neutropenia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anaemia
|
|
|
|
subjects affected / exposed
|
14 / 9135 (0.15%) |
5 / 9108 (0.05%) |
10 / 9109 (0.11%) |
occurrences causally related to treatment / all
|
7 / 15 |
3 / 5 |
7 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Normochromic normocytic anaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Leukopenia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Microcytic anaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Normocytic anaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Iron deficiency anaemia
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
2 / 4 |
1 / 1 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancytopenia
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
1 / 1 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
2 / 5 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pernicious anaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypereosinophilic syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood disorder
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Immune thrombocytopenia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhagic diathesis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
|
Vertigo
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
6 / 9108 (0.07%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vertigo positional
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vestibular disorder
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Deafness bilateral
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoacusis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ear discomfort
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sudden hearing loss
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
|
Blindness transient
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Amaurosis fugax
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cataract cortical
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cataract
|
|
|
|
subjects affected / exposed
|
17 / 9135 (0.19%) |
7 / 9108 (0.08%) |
11 / 9109 (0.12%) |
occurrences causally related to treatment / all
|
0 / 20 |
0 / 9 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blindness unilateral
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cataract nuclear
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diplopia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic retinopathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Eyelid ptosis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Glaucoma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ophthalmoplegia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Macular oedema
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pterygium
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal artery occlusion
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal vein thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal detachment
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal degeneration
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sudden visual loss
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vision blurred
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Visual acuity reduced
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Visual impairment
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vitreous haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
2 / 3 |
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Macular hole
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dacryostenosis acquired
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tolosa-Hunt syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Entropion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal vascular thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Macular fibrosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Age-related macular degeneration
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
Abdominal distension
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain upper
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
5 / 9108 (0.05%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
2 / 4 |
0 / 5 |
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
5 / 9108 (0.05%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
Acute abdomen
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
Anal fistula
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ascites
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Barrett's oesophagus
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic gastritis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colitis ischaemic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Crohn's disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Constipation
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diaphragmatic hernia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
3 / 9108 (0.03%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum intestinal
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum intestinal haemorrhagic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal perforation
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal ulcer haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dyspepsia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Enterocolitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Flatulence
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gallstone ileus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Food poisoning
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric perforation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric ulcer haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
5 / 9108 (0.05%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
3 / 7 |
1 / 5 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis erosive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis alcoholic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrooesophageal reflux disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorder
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
5 / 7 |
0 / 1 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoids
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ileus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ileus paralytic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Incarcerated inguinal hernia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
5 / 9108 (0.05%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal ischaemia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
Large intestine perforation
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal perforation
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Intestinal obstruction
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Mallory-Weiss syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Melaena
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
3 / 4 |
0 / 0 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nausea
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal achalasia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oesophagitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
12 / 9108 (0.13%) |
12 / 9109 (0.13%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 13 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 3 |
Pancreatitis haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 2 |
Pancreatitis chronic
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
13 / 9108 (0.14%) |
7 / 9109 (0.08%) |
occurrences causally related to treatment / all
|
1 / 6 |
1 / 13 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peptic ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peptic ulcer haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Small intestinal obstruction
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Stomatitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spigelian hernia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Small intestinal perforation
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Umbilical hernia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Umbilical hernia, obstructive
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Volvulus
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Vomiting
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic mass
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Subileus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anal haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lower gastrointestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dyschezia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mechanical ileus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Gastric antral vascular ectasia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine polyp
|
|
|
|
subjects affected / exposed
|
8 / 9135 (0.09%) |
9 / 9108 (0.10%) |
15 / 9109 (0.16%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
0 / 16 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal rupture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Faecaloma
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoidal haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Alcoholic pancreatitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal toxicity
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Incarcerated umbilical hernia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric mucosal lesion
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia strangulated
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ischaemic enteritis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Omental infarction
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal incarcerated hernia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Subacute pancreatitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Obstructive pancreatitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
Decubitus ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Angioedema
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
5 / 9108 (0.05%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 3 |
1 / 5 |
2 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dermatitis allergic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
2 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dermatitis exfoliative generalised
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ingrowing nail
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypersensitivity vasculitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Erythema multiforme
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperhidrosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lichen planus
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dermatomyositis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rash pruritic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin necrosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rash erythematous
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rash
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
2 / 3 |
0 / 1 |
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Psoriasis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pruritus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pemphigoid
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Leukoplakia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urticaria
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin ulcer
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urticaria chronic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic foot
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Capillaritis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Drug reaction with eosinophilia and systemic symptoms
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
Azotaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Calculus bladder
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Calculus urinary
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dysuria
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haematuria
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nephrolithiasis
|
|
|
|
subjects affected / exposed
|
6 / 9135 (0.07%) |
4 / 9108 (0.04%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nephrotic syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal failure
|
|
|
|
subjects affected / exposed
|
8 / 9135 (0.09%) |
6 / 9108 (0.07%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 7 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 2 |
Renal tubular necrosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tubulointerstitial nephritis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder mass
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic nephropathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Renal impairment
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary incontinence
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary retention
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urogenital disorder
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Chronic kidney disease
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
4 / 9108 (0.04%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Stress urinary incontinence
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Acute kidney injury
|
|
|
|
subjects affected / exposed
|
32 / 9135 (0.35%) |
22 / 9108 (0.24%) |
25 / 9109 (0.27%) |
occurrences causally related to treatment / all
|
0 / 33 |
0 / 22 |
0 / 25 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Prerenal failure
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
End stage renal disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urethral stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ureterolithiasis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
|
Adrenal insufficiency
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperparathyroidism primary
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Basedow's disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperthyroidism
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypothyroidism
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Toxic nodular goitre
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thyroid mass
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
Arthralgia
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arthropathy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Back pain
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bursitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gouty arthritis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemarthrosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Joint swelling
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lumbar spinal stenosis
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal pain
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Muscle atrophy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myalgia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myopathy
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Neck pain
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteitis
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteoarthritis
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
8 / 9108 (0.09%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 8 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteoarthropathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteoporotic fracture
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
4 / 9108 (0.04%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Polymyalgia rheumatica
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rotator cuff syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Scoliosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal osteoarthritis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral disc protrusion
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spondyloarthropathy
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal chest pain
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal stiffness
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Seronegative arthritis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Facet joint syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal synovial cyst
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
Abscess oral
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Appendicitis perforated
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
1 / 9108 (0.01%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bacteraemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
3 / 9108 (0.03%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Cellulitis
|
|
|
|
subjects affected / exposed
|
11 / 9135 (0.12%) |
9 / 9108 (0.10%) |
11 / 9109 (0.12%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 10 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Cystitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile colitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cytomegalovirus infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Dengue fever
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
|
subjects affected / exposed
|
7 / 9135 (0.08%) |
3 / 9108 (0.03%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diarrhoea infectious
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic gangrene
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dermatitis infected
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Encephalitis viral
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Encephalitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ear lobe infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulitis intestinal haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epiglottitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Folliculitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fournier's gangrene
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
6 / 9108 (0.07%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Gangrene
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Gastroenteritis
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
5 / 9108 (0.05%) |
6 / 9109 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Gastroenteritis salmonella
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis viral
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Herpes zoster
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infected skin ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Laryngitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Labyrinthitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Influenza
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Mediastinitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Liver abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Localised infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lower respiratory tract infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Meningitis aseptic
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Necrotising fasciitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Orchitis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Otitis media chronic
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
|
subjects affected / exposed
|
19 / 9135 (0.21%) |
28 / 9108 (0.31%) |
27 / 9109 (0.30%) |
occurrences causally related to treatment / all
|
0 / 21 |
0 / 28 |
0 / 32 |
deaths causally related to treatment / all
|
0 / 13 |
0 / 16 |
0 / 17 |
Pharyngitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peritonitis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Periodontitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia klebsiella
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative wound infection
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
3 / 9108 (0.03%) |
4 / 9109 (0.04%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary tuberculosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pyelitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pyelonephritis
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
3 / 9108 (0.03%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pyelonephritis acute
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sepsis
|
|
|
|
subjects affected / exposed
|
22 / 9135 (0.24%) |
19 / 9108 (0.21%) |
18 / 9109 (0.20%) |
occurrences causally related to treatment / all
|
0 / 24 |
0 / 19 |
0 / 18 |
deaths causally related to treatment / all
|
0 / 13 |
0 / 11 |
0 / 8 |
Skin infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Septic shock
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
9 / 9108 (0.10%) |
8 / 9109 (0.09%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 9 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 8 |
0 / 5 |
Subcutaneous abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tooth abscess
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Superinfection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tracheobronchitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
|
subjects affected / exposed
|
18 / 9135 (0.20%) |
11 / 9108 (0.12%) |
17 / 9109 (0.19%) |
occurrences causally related to treatment / all
|
0 / 20 |
0 / 11 |
0 / 19 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Upper respiratory tract infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tuberculosis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Vestibular neuronitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Viral myocarditis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
9 / 9108 (0.10%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 10 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
|
subjects affected / exposed
|
11 / 9135 (0.12%) |
9 / 9108 (0.10%) |
7 / 9109 (0.08%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 11 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Anal abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rectal abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vaginal abscess
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Groin abscess
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abscess limb
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal bacteraemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Campylobacter infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haematoma infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Febrile infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary sepsis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
3 / 9108 (0.03%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Neuroborreliosis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia urinary tract infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abscess neck
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
3 / 9108 (0.03%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia bacteraemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Helicobacter infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia necrotising
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Subdiaphragmatic abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
Biliary sepsis
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Periorbital cellulitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infective exacerbation of chronic obstructive airways disease
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Wound sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Infected cyst
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral toxoplasmosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Staphylococcal infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Implant site infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Klebsiella bacteraemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis infectious
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic foot infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
2 / 9108 (0.02%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Intervertebral discitis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bacterial infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis infective
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Klebsiella infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Borrelia infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Biliary tract infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atypical mycobacterial infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Parainfluenzae virus infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mycobacterial infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peritonitis bacterial
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Keratitis bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Soft tissue infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
2 / 9108 (0.02%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Respiratory tract infection
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Cholecystitis infective
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Device related infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Biliary tract infection bacterial
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
Infectious pleural effusion
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis norovirus
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural infection
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colonic abscess
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Medical device site joint infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Varicella zoster virus infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis infective
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infected bite
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bacterial abdominal infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
COVID-19
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 3 |
Nephritis bacterial
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine infection
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Complicated appendicitis
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
COVID-19 pneumonia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
Metabolism and nutrition disorders
|
|
|
|
Diabetes mellitus
|
|
|
|
subjects affected / exposed
|
5 / 9135 (0.05%) |
6 / 9108 (0.07%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 6 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes mellitus inadequate control
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
5 / 9108 (0.05%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dehydration
|
|
|
|
subjects affected / exposed
|
4 / 9135 (0.04%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
Diabetic ketoacidosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cachexia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
2 / 9109 (0.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
Fluid overload
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gout
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
1 / 9108 (0.01%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperammonaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
|
subjects affected / exposed
|
3 / 9135 (0.03%) |
1 / 9108 (0.01%) |
3 / 9109 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
Hypomagnesaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypokalaemia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
1 / 9108 (0.01%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyponatraemia
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
3 / 9108 (0.03%) |
5 / 9109 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypovolaemia
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lactic acidosis
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperglycaemic hyperosmolar nonketotic syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
1 / 9108 (0.01%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic complication
|
|
|
|
subjects affected / exposed
|
0 / 9135 (0.00%) |
0 / 9108 (0.00%) |
1 / 9109 (0.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Marasmus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
Type 2 diabetes mellitus
|
|
|
|
subjects affected / exposed
|
1 / 9135 (0.01%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic metabolic decompensation
|
|
|
|
subjects affected / exposed
|
2 / 9135 (0.02%) |
0 / 9108 (0.00%) |
0 / 9109 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |